CASI Pharmaceuticals (ENM) Stock Statistics & Valuation Metrics

CASI Pharmaceuticals has a market cap or net worth of CHF2.37M. The enterprise value is CHF40.23.

CASI Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

CASI Pharmaceuticals’s return on equity (ROE) is 1.29 and return on invested capital (ROIC) is -2115.85%.

The current PE Ratio of CASI Pharmaceuticals is ―. CASI Pharmaceuticals’s PEG ratio is -0.28.

In the last 12 months, CASI Pharmaceuticals had revenue of 20.71M and earned -48.06M in profits. Earnings per share was -2.59.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

CASI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CASI Pharmaceuticals upcoming earnings date is Nov 13, 2026, TBA (Confirmed).

CASI Pharmaceuticals as a current ratio of 0.27, with Debt / Equity ratio of -69.50%

In the past 12 months, CASI Pharmaceuticals has paid 0.00 in taxes.

CASI Pharmaceuticals EV to EBITDA ratio is -0.86, with an EV/FCF ratio of -1.81.

CASI Pharmaceuticals has CHF3.77M in cash and marketable securities with CHF40.50M in debt, giving a net cash position of -CHF36.73M billion.

Gross margin is 59.97%, with operating margin of -206.87%, and net profit margin of -232.03%.

The average price target for CASI Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―